Aim ImmunoTech Urges Shareholders To Vote On The White Universal Proxy Card "For" All 4 Incumbent Board Members; Believes Future Of The Co And That The Current Board Is Best Positioned To Continue Clinical Trial Momentum, Commercialize Ampligen And...
Aim ImmunoTech Urges Shareholders To Vote On The White Universal Proxy Card "For" All 4 Incumbent Board Members; Believes Future Of The Co And That The Current Board Is Best Positioned To Continue Clinical Trial Momentum, Commercialize Ampligen And...
Aim ImmunoTech Urges Shareholders To Vote On The White Universal Proxy Card "For" All 4 Incumbent Board Members; Believes Future Of The Co And That The Current Board Is Best Positioned To Continue Clinical Trial Momentum, Commercialize Ampligen And Deliver Long-Term Value For Shareholders
AIM ImmunoTech敦促股東在白色普遍代理卡上投票支持所有4名現任董事會成員；相信公司的未來以及當前董事會是繼續臨床試驗勢頭、商業化Ampligen併爲股東提供長期價值的最佳位置。
Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders
相信年度會議的結果對公司的未來至關重要，當前董事會是繼續臨床試驗勢頭、商業化Ampligen併爲股東提供長期價值的最佳位置。
In AIM's View, the Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Attempts to Gain Control of the Board – Without Putting this to a Shareholder Vote – Is Grossly Irresponsible and Not in the Best Interests of All Shareholders
在AIM看來，激進派團體計劃向個人報銷超過500萬的失敗嘗試以控制董事會——而不提交股東投票——是極其不負責任的，且不符合所有股東的最佳利益。
Reminds Shareholders that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Recommended Against Giving the Dissident Nominees Control of the AIM Board, Specifically Citing Their Lack of a Plan, Among Other Issues
提醒股東，兩家領先的獨立代理諮詢公司——ISS和玻璃劉易斯——建議反對授予反對派提名人控制AIM董事會，特別指出他們缺乏計劃等其他問題。
Highlights Activist Group Nominees Todd A. Deutsch's and Robert L. Chioini's Checkered Pasts and Affiliations with Securities Law Criminals – and that Mr. Chioini Was Fired as CEO of Rockwell Medical for His "Sustained Mismanagement" and "Blatant Disregard for Shareholder Concerns"1
強調激進派團體提名人Todd A. Deutsch和Robert L. Chioini的黑暗過往及與證券法罪犯的關係——而Chioini因其「持續管理不善」和「公然無視股東關切」而被Rockwell Medical解僱。
Questions How Activist Group Nominee Paul Sweeney Could Function as an Independent Director Given that Mr. Kellner is Apparently the Biggest Investor in Mr. Sweeney's Private Equity Firm
質疑激進派團體提名人Paul Sweeney如何能作爲獨立董事職能，因爲Kellner顯然是Sweeney的股權投資公司最大的投資者。
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders (the "Annual Meeting"), presently scheduled for December 17, 2024:
AIM ImmunoTech Inc. (紐交所:AIM)（"AIM"或"公司"）今天發佈了以下聲明，涉及即將於2024年12月17日舉行的股東年度會議（"年度會議"）。
With the Annual Meeting quickly approaching, it is critical that shareholders vote on the WHITE universal proxy card to re-elect all four current members of our Board of Directors (the "Board"). As shareholders consider this important decision, we ask that they keep the following in mind:
隨着年度會議的臨近，股東在白色普遍代理卡上投票重新選舉我們董事會的所有四名現任成員（"董事會"）至關重要。在股東考慮這一重要決定時，我們請求他們牢記以下幾點：
譯文內容由第三人軟體翻譯。
